» Articles » PMID: 12654969

Staging Disease Severity in Pathologically Confirmed Cases of Frontotemporal Dementia

Overview
Journal Neurology
Specialty Neurology
Date 2003 Mar 26
PMID 12654969
Citations 111
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To devise a staging scheme for addressing the severity of atrophy in patients with pathologically proven frontotemporal dementia (FTD) and determine any relationship with clinical indices.

Methods: Twenty-four cases with clinical and pathologic features of FTD were selected using standard inclusion and exclusion criteria from 125 dementia cases collected in Sydney, Australia, over an 8.5-year period. Patterns of gross atrophy were determined in two coronal brain slices. Reproducibility of a four-stage severity scheme was tested. Nonparametric statistics were used to determine relationships between the stage of atrophy and clinical indices (age at death, duration from diagnosis, and clinical severity at death).

Results: The FTD cases studied could be reliably grouped (kappa = 0.97) into four progressively severe stages of global atrophy. Initial mild atrophy occurred in the orbital and superior medial frontal cortices and hippocampus (stage 1), progressed to involve the other anterior frontal regions, temporal cortices, and basal ganglia (stage 2), then involved all remaining tissue in these coronal slices (stage 3), until very marked atrophy was observed in all areas (stage 4). These stages correlated with disease duration and clinical dementia severity, lending validity to the progressive nature of the staging scheme.

Conclusions: The authors have identified a reproducible staging system for the severity of gross atrophy in cases of FTD. This staging scheme provides the required framework to compare different research indices and determine correlates relating to time and disease progression in FTD-information necessary to determine core disease processes and etiologic factors.

Citing Articles

.

Pasternak M, Mirza S, Luciw N, Mutsaerts H, Petr J, Thomas D Alzheimers Dement. 2024; 20(5):3525-3542.

PMID: 38623902 PMC: 11095434. DOI: 10.1002/alz.13750.


Early detection of diseases causing dementia using digital navigation and gait measures: A systematic review of evidence.

cepukaityte G, Newton C, Chan D Alzheimers Dement. 2024; 20(4):3054-3073.

PMID: 38425234 PMC: 11032572. DOI: 10.1002/alz.13716.


Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2 p.T487I-linked amyotrophic lateral sclerosis and frontotemporal dementia.

Nementzik L, Thumbadoo K, Murray H, Gordon D, Yang S, Blair I Brain Pathol. 2023; 34(3):e13230.

PMID: 38115557 PMC: 11007053. DOI: 10.1111/bpa.13230.


Elevated GRO-α and IL-18 in serum and brain implicate the NLRP3 inflammasome in frontotemporal dementia.

Lok H, Katzeff J, Hodges J, Piguet O, Fu Y, Halliday G Sci Rep. 2023; 13(1):8942.

PMID: 37268663 PMC: 10238432. DOI: 10.1038/s41598-023-35945-4.


A Brief Overview of Neutrophils in Neurological Diseases.

Chakraborty S, Tabrizi Z, Bhatt N, Franciosa S, Bracko O Biomolecules. 2023; 13(5).

PMID: 37238612 PMC: 10216532. DOI: 10.3390/biom13050743.